An Open-label, Randomised, Phase I, Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI

Trial Profile

An Open-label, Randomised, Phase I, Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Nov 2017 Results of pooled data from two phase1 trial assessing impact of food or gastric pH modification (omeprazole) on the exposure and safety/tolerability of osimertinib and its metabolites in patient with EGFR mutation positive advanced non-small lung cancer, were published in the Journal of Clinical Pharmacology.
    • 17 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jan 2018.
    • 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top